Human microbiome has co-evolved with humans for centuries, which includes bacteria, viruses, fungi, Achaeans etc. The human microbiome is now one of the fastest growing areas of biology, and is considered as a newly discovered organ with the potential to have a tremendous impact on human health. Microbiome therapeutics are therapies that are designed to disrupt unhealthy microbial ecological networks and that catalyse the establishment of healthy ones.
Scope of the Report:
This report studies the Human Microbiome Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Human Microbiome Therapeutics market by product type and applications/end industries.
One of the major drivers for this market is side effects of the existing treatments. Various medicines available in the market have several side-effects including minor headaches. These medicines may also impart serious side-effects such as liver or kidney injury, heart problems, and even death. The seriousness of side-effects drives the need for innovative treatment technologies, such as human microbiome therapeutics, that have reduced the negative impact on the human body. The demand for microbiome therapeutics is increasing since it provides treatment sans chemicals.
The latest trend gaining momentum in the market is growing investments from venture capitalists. Venture capitalists are capitalizing on the need for effective treatment and are offering therapeutic treatment solutions to treat disorders such as autoimmune disorders, infections, and cancer.
The global Human Microbiome Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Human Microbiome Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Enterome Bioscience
Rebiotix
Seres Therapeutics
Vedanta Biosciences
Bristol-Myers Squibb
Johnson & Johnson
Takeda Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
FMT
Microbiome Drugs
Market Segment by Applications, can be divided into
C. difficile
Crohn’s Disease
Inflammatory Bowel Disease
Diabetes
Others
Frequently Asked Questions
Table Of Content
Table of Contents
1 Human Microbiome Therapeutics Market Overview
1.1 Product Overview and Scope of Human Microbiome Therapeutics
1.2 Classification of Human Microbiome Therapeutics by Types
1.2.1 Global Human Microbiome Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Human Microbiome Therapeutics Revenue Market Share by Types in 2017
1.2.3 FMT
1.2.4 Microbiome Drugs
1.3 Global Human Microbiome Therapeutics Market by Application
1.3.1 Global Human Microbiome Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 C. difficile
1.3.3 Crohn’s Disease
1.3.4 Inflammatory Bowel Disease
1.3.5 Diabetes
1.3.6 Others
1.4 Global Human Microbiome Therapeutics Market by Regions
1.4.1 Global Human Microbiome Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Human Microbiome Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Human Microbiome Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Human Microbiome Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Human Microbiome Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Human Microbiome Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Human Microbiome Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Enterome Bioscience
2.1.1 Business Overview
2.1.2 Human Microbiome Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Enterome Bioscience Human Microbiome Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Rebiotix
2.2.1 Business Overview
2.2.2 Human Microbiome Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Rebiotix Human Microbiome Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Seres Therapeutics
2.3.1 Business Overview
2.3.2 Human Microbiome Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Seres Therapeutics Human Microbiome Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Vedanta Biosciences
2.4.1 Business Overview
2.4.2 Human Microbiome Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Vedanta Biosciences Human Microbiome Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Human Microbiome Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bristol-Myers Squibb Human Microbiome Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Johnson & Johnson
2.6.1 Business Overview
2.6.2 Human Microbiome Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Johnson & Johnson Human Microbiome Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Takeda Pharmaceutical
2.7.1 Business Overview
2.7.2 Human Microbiome Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Takeda Pharmaceutical Human Microbiome Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Human Microbiome Therapeutics Market Competition, by Players
3.1 Global Human Microbiome Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Human Microbiome Therapeutics Players Market Share
3.2.2 Top 10 Human Microbiome Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Human Microbiome Therapeutics Market Size by Regions
4.1 Global Human Microbiome Therapeutics Revenue and Market Share by Regions
4.2 North America Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Human Microbiome Therapeutics Revenue by Countries
5.1 North America Human Microbiome Therapeutics Revenue by Countries (2013-2018)
5.2 USA Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Human Microbiome Therapeutics Revenue by Countries
6.1 Europe Human Microbiome Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Human Microbiome Therapeutics Revenue by Countries
7.1 Asia-Pacific Human Microbiome Therapeutics Revenue by Countries (2013-2018)
7.2 China Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Human Microbiome Therapeutics Revenue by Countries
8.1 South America Human Microbiome Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Human Microbiome Therapeutics by Countries
9.1 Middle East and Africa Human Microbiome Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Human Microbiome Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Human Microbiome Therapeutics Market Segment by Type
10.1 Global Human Microbiome Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Human Microbiome Therapeutics Market Forecast by Type (2018-2023)
10.3 FMT Revenue Growth Rate (2013-2023)
10.4 Microbiome Drugs Revenue Growth Rate (2013-2023)
11 Global Human Microbiome Therapeutics Market Segment by Application
11.1 Global Human Microbiome Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Human Microbiome Therapeutics Market Forecast by Application (2018-2023)
11.3 C. difficile Revenue Growth (2013-2018)
11.4 Crohn’s Disease Revenue Growth (2013-2018)
11.5 Inflammatory Bowel Disease Revenue Growth (2013-2018)
11.6 Diabetes Revenue Growth (2013-2018)
11.7 Others Revenue Growth (2013-2018)
12 Global Human Microbiome Therapeutics Market Size Forecast (2018-2023)
12.1 Global Human Microbiome Therapeutics Market Size Forecast (2018-2023)
12.2 Global Human Microbiome Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Human Microbiome Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Human Microbiome Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Human Microbiome Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Human Microbiome Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Human Microbiome Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Inquiry For Buying
Human Microbiome Therapeutics
Request Sample
Human Microbiome Therapeutics
